Amyris Inc Overview

Amyris Inc is a corporation that specializes in industrial biotechnology. It designs, manufactures, and sells products in a wide range of consumer and industrial markets, including as cosmetics, flavors and perfumes, solvents and cleaners, polymers, lubricants, healthcare products, and fuels. The company’s operations are scattered throughout the world, with the majority of revenue generated in the United States. Revenue is generated via the sale of renewable products, intellectual property licenses and royalties, grants, and joint research and development services.

Company’s Financial Performance

Amyris, Inc. (AMRS) reported a quarterly loss of $0.52 per share, compared to the Zacks Consensus Estimate of $0.20. This compared to a loss of $0.43 per share the previous year. These values have been adjusted to account for non-recurring items.

This quarterly report indicates a -160% earnings surprise. This company was predicted to post a loss of $0.21 per share a quarter ago, but instead posted a loss of $0.44, producing a -109.52% surprise.

For the last four quarters, the company has failed to outperform consensus EPS estimates.

Amyris, Inc., a company in the Zacks Chemical – Specialty category, reported revenue of $75.8 million for the quarter ending December 2022, falling 27.18% short of the Zacks Consensus Estimate. This compares to $64.78 million in sales the previous year. For the last four quarters, the company has failed to meet consensus revenue estimates.

What’s next ?

As Amyris, Inc. has underperformed the market so far this year, investors are wondering what’s next for the stock.

There are no simple solutions to this critical question, but one dependable metric that can assist investors is the company’s profits outlook. This includes not just the current consensus earnings predictions for the next quarter(s), but also how these expectations have evolved recently.


According to empirical research, there is a high association between short-term stock fluctuations and changes in earnings estimate revisions. Investors can watch such changes on their own or use a tried-and-true grading tool like the Zacks Rank, which has a proven track record of capitalizing on earnings estimate modifications.

Amyris, Inc. ‘s estimated revisions history has been mixed ahead of this earnings release. While the degree and direction of estimate revisions may alter following the company’s recently issued earnings report, the stock currently has a Zacks Rank #3 (Hold). As a result, the stock is projected to perform in accordance with the market in the near future.

But on the other hand, based on data provided by InvestorsObserver, that average rating awards the stock an Analyst Rating of 18, which indicates it ranks higher than 18 other stocks. Amyris Inc (AMRS) is expected to gain 475.41% over the next twelve months, according to analysts who follow the stock. These same analysts rate the stock as a Buy on average.


Finally, it is unclear whether Amyris Corp will return anytime soon. In recent years, the corporation has encountered major issues, including continuous losses and excessive debt levels. Yet, there are some encouraging signs, such as the company’s collaborations with key companies in the cosmetics and fragrance industries.

The renewable chemicals business is also quickly expanding, with increased public and private sector interest and investment. Amyris Inc, as a market leader, may be well-positioned to capitalize on this trend.

Before making any investment decisions in Amyris Inc, investors should carefully evaluate these considerations, as well as keep a close check on the company’s financials and developments in the renewable chemicals business.


Please continue to read new articles here about merchandise assessed by Waytrade.


Please enter your comment!
Please enter your name here